84 related articles for article (PubMed ID: 21947232)
1. Remarkable extension of PAI-1 half-life surprisingly brings no changes to its structure.
Jankun J; Yang J; Zheng H; Han FQ; Al-Senaidy A; Skrzypczak-Jankun E
Int J Mol Med; 2012 Jan; 29(1):61-4. PubMed ID: 21947232
[TBL] [Abstract][Full Text] [Related]
2. VLHL plasminogen activator inhibitor spontaneously reactivates from the latent to active form.
Jankun J; Aleem AM; Selman SH; Basrur V; Skrzypczak-Jankun E
Int J Mol Med; 2009 Jan; 23(1):57-63. PubMed ID: 19082507
[TBL] [Abstract][Full Text] [Related]
3. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
4. Very long half-life plasminogen activator inhibitor type 1 reduces bleeding in a mouse model.
Jankun J; Selman SH; Keck RW; Łysiak-Szydłowska W; Skrzypczak-Jankun E
BJU Int; 2010 May; 105(10):1469-76. PubMed ID: 19912209
[TBL] [Abstract][Full Text] [Related]
5. Systemic or topical application of plasminogen activator inhibitor with extended half-life (VLHL PAI-1) reduces bleeding time and total blood loss.
Jankun J; Keck R; Selman SH; Skrzypczak-Jankun E
Int J Mol Med; 2010 Oct; 26(4):501-4. PubMed ID: 20818488
[TBL] [Abstract][Full Text] [Related]
6. Distal hinge of plasminogen activator inhibitor-1 involves its latency transition and specificities toward serine proteases.
Wang Q; Shaltiel S
BMC Biochem; 2003 Jul; 4():5. PubMed ID: 12848892
[TBL] [Abstract][Full Text] [Related]
7. Protein conformational change delayed by steric hindrance from an N-linked glycan.
Bager R; Johansen JS; Jensen JK; Stensballe A; Jendroszek A; Buxbom L; Sørensen HP; Andreasen PA
J Mol Biol; 2013 Aug; 425(16):2867-77. PubMed ID: 23702291
[TBL] [Abstract][Full Text] [Related]
8. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Stoop AA; Eldering E; Dafforn TR; Read RJ; Pannekoek H
J Mol Biol; 2001 Jan; 305(4):773-83. PubMed ID: 11162091
[TBL] [Abstract][Full Text] [Related]
9. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
Björquist P; Ehnebom J; Inghardt T; Hansson L; Lindberg M; Linschoten M; Strömqvist M; Deinum J
Biochemistry; 1998 Feb; 37(5):1227-34. PubMed ID: 9477948
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor type-1 mutants regulate angiogenesis of human umbilical and lung vascular endothelial cells.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Selman SH; Jankun J
Oncol Rep; 2004 Dec; 12(6):1155-62. PubMed ID: 15547731
[TBL] [Abstract][Full Text] [Related]
11. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.
Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J
Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669
[TBL] [Abstract][Full Text] [Related]
12. PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells.
Jankun J; Aleem AM; Specht Z; Keck RW; Lysiak-Szydlowska W; Selman SH; Skrzypczak-Jankun E
Int J Mol Med; 2007 Jul; 20(1):11-20. PubMed ID: 17549383
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor with very long half-life (VLHL PAI-1) can reduce bleeding in PAI-1-deficient patients.
Jankun J; Skrzypczak-Jankun E
Cardiovasc Hematol Disord Drug Targets; 2013 Aug; 13(2):144-50. PubMed ID: 23988002
[TBL] [Abstract][Full Text] [Related]
14. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Dekker RJ; Eichinger A; Stoop AA; Bode W; Pannekoek H; Horrevoets AJ
J Mol Biol; 1999 Oct; 293(3):613-27. PubMed ID: 10543954
[TBL] [Abstract][Full Text] [Related]
15. The Bbeta-sheet in the PAI-1 molecule plays an important role for its stability.
Sui GC; Wiman B
Thromb Haemost; 2000 Jun; 83(6):896-901. PubMed ID: 10896245
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.
Nar H; Bauer M; Stassen JM; Lang D; Gils A; Declerck PJ
J Mol Biol; 2000 Mar; 297(3):683-95. PubMed ID: 10731421
[TBL] [Abstract][Full Text] [Related]
17. S35225 is a direct inhibitor of Plasminogen Activator Inhibitor type-1 activity in the blood.
Rupin A; Gaertner R; Mennecier P; Richard I; Benoist A; De Nanteuil G; Verbeuren TJ
Thromb Res; 2008; 122(2):265-70. PubMed ID: 18177924
[TBL] [Abstract][Full Text] [Related]
18. Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1.
Gong L; Liu M; Zeng T; Shi X; Yuan C; Andreasen PA; Huang M
J Biol Chem; 2015 Oct; 290(43):25795-804. PubMed ID: 26324706
[TBL] [Abstract][Full Text] [Related]
19. Kinetically controlled folding of the serpin plasminogen activator inhibitor 1.
Wang Z; Mottonen J; Goldsmith EJ
Biochemistry; 1996 Dec; 35(51):16443-8. PubMed ID: 8987976
[TBL] [Abstract][Full Text] [Related]
20. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
